Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The present study was undertaken to investigate thoroughly the preclinical psychopharmacological profile of venlafaxine, testing a wide range of doses in animal models indicative of antidepressant-like effects. Venlafaxine was found to be active in mouse forced swimming test (at 8, 16, 32 and 64 mg/kg) and to increase spontaneous locomotor activity (at 16, 32 and 64 mg/kg). Venlafaxine antagonised apomorphine-induced (16 mg/kg) hypothermia (at 2, 4, 8, 16, 32 and 64 mg/kg). Pretreatment with PCPA significantly attenuated the anti-immobility effects of venlafaxine (8 and 16mg/kg; P< 0.01) in the mouse forced swimming test. Venlafaxine at a dose of 32 mg/kg remained active, despite PCPA pretreatment. DSP-4 significantly attenuated the anti-immobility effects of venlafaxine (16 mg/kg; P < 0.05), whereas venlafaxine at 32 mg/kg remained active, despite DSP-4 pretreatment. Venlafaxine was active in the forced swimming test when administered at sub-effective doses in combination with (+/-) pindolol (venlafaxine: 1 and 2 mg/kg), RU 24969 (venlafaxine: 1, 2 and 4 mg/kg), 8-OH-DPAT (venlafaxine: 4 mg/kg), clonidine (venlafaxine: 1, 2 and 4 mg/kg), lithium (venlafaxine: 1, 2, and 4 mg/kg) and quinine (venlafaxine: 1 and 2 mg/kg). Prior administration with NAN-190 antagonised the anti-immobility effects of venlafaxine (8, 16 and 32 mg/kg). Interaction studies did not induce changes in locomotor activity. The results of the present study indicated that, at low doses, venlafaxine inhibited serotonin reuptake, while at higher doses it inhibited both serotonin and noradrenaline reuptake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Venlafaxine’s effect on noradrenaline reuptake is dose-dependent, starting on doses of around 225 mg daily. When the daily dose is lower, it acts on serotonin reuptake only, like a common SSRI [36, 37].”
From Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study (2016) · cites this paper as [37]
In the citing paper
“Venlafaxine is a phenylethylamine derivative inhibiting the reuptake of serotonin/5-HT; norepinephrine/NE; and to a lesser extent dopamine/DA (Bolden-Watson and Richelson, 1993; Redrobe et al., 1998).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Redrobe et al., 1998
Citations
Cites
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 4,063
Tricklebank, M. D., Forler, C., & Fozard, J. R. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90714-3 · Cited by 675 · cited 2×
“E⁄ects include hypothermia in both mice and rats (Goodwin et al. 1985; Hjorth 1985), a characteristic i5-HT syndromei in rats ( Tricklebank et al. 1984 ) and alterations in rat feeding behaviour (Hutson et al. 1988).”
BackgroundPRESYNAPTIC RECEPTORS AND THEIR ROLE IN THE REGULATION OF TRANSMITTER RELEASE.
Langer, S. Z. (1977) · Cited by 611
Functional Correlates of Serotonin 5-HT1Recognition Sites
Hoyer, D. (1988) · Journal of Receptor Research · doi:10.3109/10799898809048978 · Cited by 562 · cited 2×
“In addition to its ability to bind to 5-HT1A receptors (Hoyer 1988) and antagonise the postsynaptic behavioural e¤ects of 8-OHDPAT (Tricklebank et al. 1987; Lucki 1989), pindolol also acts as an antagonist at presynaptic 5-HT1A receptor sites (Lucki 1992).”
BackgroundMuth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374 · cited 2×
“Venlafaxine has not been shown to inhibit monoamine oxidase (Muth et al. 1986).”
BackgroundResult5-Hydroxytryptamine Receptor Subtypes
Peroutka, S. J. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000401 · Cited by 358
Behavioural despair in mice : A primary screening test for antidepressants
Porsalt, R. D. (1977) · Medical Entomology and Zoology · Cited by 332
Goodwin, G. M., De Souza, R. J., & Green, A. R. (1985) · Neuropharmacology · doi:10.1016/0028-3908(85)90153-4 · Cited by 252 · cited 1×
“E¤ects include hypothermia in both mice and rats (Goodwin et al. 1985; Hjorth 1985), a characteristic 5-HT syndrome in rats (Tricklebank et al. 1984) and alterations in rat feeding behaviour (Hutson et al. 1988).”
BackgroundHypothermia in the rat induced by the potent serotoninergic agent 8-OH-DPAT
Hjorth, S. (1985) · Journal of Neural Transmission · doi:10.1007/bf01253058 · Cited by 241
Glennon, R. A., Naiman, N. A., Pierson, M. E., Titeler, M., Lyon, R. A., & Weisberg, E. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90212-9 · Cited by 184 · cited 2×
“NAN 190 is an arylpiperazine derivative which has a high a¦nity for the 5-HT1A receptor and it has been shown to act as a 5-HT1A antagonist in vivo (Glennon et al. 1988; Chojnacka-Wojcik et al. 1991).”
Background
Cited by
Forced swimming test in mice: A review of antidepressant activity
Petit-Demouliere, B., Chenu, F., & Bourin, M. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2048-7 · Cited by 1,003
“…(1984), Eschalier et al. (1983), Kato et al. (1998), Luttinger et al. (1985), Malinge et al. (1988), Miura et al. (1996), Mogilnicka et al. (1987), Redrobe et al. (1998), Rogoz et al. (1999), Scotto di Tella and Mercier (1981), Stenger et al. (1987), Szymczyk and Zebrowska- Lupina (2000), Zocchi…”
Self-citationRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
The olfactory bulbectomised rat as a model of depression
Song, C., & Leonard, B. E. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.010 · Cited by 698
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Cryan, J. F., O'Leary, O. F., Jin, S.-H., Friedland, J. C., Ouyang, M., Hirsch, B. R., Page, M. E., Dalvi, A., Thomas, S. A., & Lucki, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401080101 · Cited by 252
Bourin, M., Mocaër, E., & Porsolt, R. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0414 · Cited by 226
“Imipramine + pindolol 185 (11) [25] 227 (3)”
Self-citationMachado, D. G., Bettio, L. E. B., Cunha, M. P., Santos, A. R. S., Pizzolatti, M. G., Brighente, I. M. C., & Rodrigues, A. L. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.021 · Cited by 208
Ohgi, Y., Futamura, T., Kikuchi, T., & Hashimoto, K. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.12.003 · Cited by 207
Machado, D. G., Bettio, L. E. B., Cunha, M. P., Capra, J. C., Dalmarco, J. B., Pizzolatti, M. G., & Rodrigues, A. L. S. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.03.004 · Cited by 190
How valuable are animal models in defining antidepressant activity?
Bourin, M., Fiocco, A. J., & Clenet, F. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.178 · Cited by 158
Self-citationBrocardo, P. S., Budni, J., Kaster, M. P., Santos, A. R. S., & Rodrigues, A. L. S. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.016 · Cited by 150
Cervo, L., Canetta, A., Calcagno, E., Burbassi, S., Sacchetti, G., Caccia, S., Fracasso, C., Albani, D., Forloni, G., & Invernizzi, R. W. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1816-05.2005 · Cited by 142
“Previous studies reported no effects of PCPA or the serotonergic neurotoxin 5,7-dihydroxytryptamine on immobility time in mice and rats (Cervo and Samanin, 1991; Borsini, 1995; Redrobe et al., 1998; Page et al., 1999).”
Machado, D. G., Kaster, M. P., Binfaré, R. W., Dias, M., Santos, A. R. S., Pizzolatti, M. G., Brighente, I. M. C., & Rodrigues, A. L. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.11.004 · Cited by 150
The behavioral actions of lithium in rodent models: Leads to develop novel therapeutics
O’Donnell, K. C., & Gould, T. D. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.04.002 · Cited by 137
“This adjunctive effect of lithium, which it shares (though not identically) with clonidine and quinine, has been shown for a number of different kinds of antidepressants, including SSRIs, MAOIs, tricyclic, and atypical antidepressants (Malinge et al., 1988; Bourin et al., 1991; Hascoet et al., 1994; Nixon et al., 1994…”
BackgroundResultAnimal models of depression: are there any?
O'Neil, M. F., & Moore, N. A. (2003) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.496 · Cited by 133
“It is likely that this effect is due to the agonist action of the compound on dopaminergic receptors on noradrenergic terminals, preventing noradrenaline release (Redrobe et al., 1998).”
BackgroundRamamoorthy, R., Radhakrishnan, M., & Borah, M. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f3cfd4 · Cited by 130
“VLF, in a lower dose range (2–8 mg/kg), mainly influences the serotonergic system, whereas at higher doses the involvement of the norepinephrine (NE) system predominates (Béı̈que et al., 2000; Redrobe et al., 1998).”
BackgroundCryan, J. F., Dalvi, A., Jin, S., Hirsch, B. R., Lucki, I., & THOMAS, S. A. (2001) · PubMed · Cited by 129
Effect of various classes of antidepressants in behavioral paradigms of despair
Kulkarni, S. K., & Dhir, A. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.002 · Cited by 133
Millan, M. J., Dekeyne, A., Papp, M., Rochelle, C. D. L., MacSweeny, C., Peglion, J.-L., & Brocco, M. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29416-7 · Cited by 117
“, 2000), but its robust effects in mice (Redrobe et al., 1998) were confirmed herein.”
Melo, F. H. C., Moura, B. A., de Sousa, D. P., Vasconcelos, S. M. M., Macêdo, D. S., Fonteles, M. M. D. F., Viana, G. S. D. B., & de Sousa, F. C. F. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00850.x · Cited by 122
Wong, D. T., & Bymaster, F. P. (2002) · Progress in Drug Research · doi:10.1007/978-3-0348-8183-8_5 · Cited by 112
Kwon, S., Lee, B., Kim, M., Lee, H., Park, H., & Hahm, D. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.015 · Cited by 118
Yau, J. L. W., Noble, J., Hibberd, C., Rowe, W. B., Meaney, M. J., Morris, R. G. M., & Seckl, J. R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-04-01436.2002 · Cited by 106
Can, Ö. D., Özkay, Ü. D., & Üçel, U. İ. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.017 · Cited by 118
Gavioli, E. C., Vaughan, C. W., Marzola, G., Guerrini, R., Mitchell, V. A., Zucchini, S., de Lima, T. C. M., Rae, G. A., Salvadori, S., Regoli, D. C., et al. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0939-0 · Cited by 109
“Similar monoamine depletion by these agents has been reported in mice ( Redrobe et al. 1998 ).”
BackgroundConnor, T. J., Kelliher, P., Shen, Y., Harkin, A., Kelly, J. P., & Leonard, B. E. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00192-6 · Cited by 102
Dhir, A., & Kulkarni, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.02.008 · Cited by 101
“Venlafaxine, a novel antidepressant is an inhibitor of both serotonin and norepinephrine transporters (SERT and NET, respectively) (Redrobe et al., 1998).”
BackgroundCryan, J. F., Dalvi, A., Jin, S.-H., Hirsch, B. R., Lucki, I., & Thomas, S. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29424-6 · Cited by 52
David, D. J. P., Bourin, M., Jego, G., Przybylski, C., Jolliet, P., & Gardier, A. M. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705538 · Cited by 88
“(Redrobe et al., 1998b, c).”
BackgroundMethodResultInfluentialSelf-citationPosser, T., Kaster, M. P., Baraúna, S. C., Rocha, J. B. T., Rodrigues, A. L. S., & Leal, R. B. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.055 · Cited by 86
Anxiolytic-Like Effects of Antidepressants After Acute Administration in a Four-Plate Test in Mice
Hascoët, M., Bourin, M., Colombel, M. C., Fiocco, A. J., & Baker, G. B. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00191-4 · Cited by 80
Self-citationKaster, M. P., Santos, A. R. S., & Rodrigues, A. L. S. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.05.025 · Cited by 75
Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
Simon, J. S., Aguiar, L. M., Kunz, N. R., & Lei, D. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.004 · Cited by 69
Zhao, J., Jung, Y.-H., Jang, C.-G., Chun, K.-H., Kwon, S. W., & Lee, J. (2015) · Scientific Reports · doi:10.1038/srep08890 · Cited by 66
Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats
Sharma, N., Jamwal, S., & Kumar, P. (2016) · Pathophysiology · doi:10.1016/j.pathophys.2016.03.002 · Cited by 69
Redrobe, J. P., Dumont, Y., Fournier, A., Baker, G. B., & Quirion, R. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.029 · Cited by 72
“Previous studies have shown that the PCPA treatment used in the present study produces partial but highly significant reductions (over 60%) in brain 5-HT levels, while noradrenaline and dopamine levels are not affected [ 40 ,41].”
ResultSelf-citationde Oliveira, R. A., Cunha, G. M. A., Borges, K. D. M., de Bruin, G. S., Filho, E. A. S., Viana, G. S. D. B., & de Bruin, V. M. S. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.09.001 · Cited by 75
The antidepressant activity of inositol in the forced swim test involves 5-HT2 receptors
Einat, H., Clénet, F., Shaldubina, A., Belmaker, R. H., & Bourin, M. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00314-4 · Cited by 66
Self-citationLin, P., Wang, C., Xu, B., Gao, S., Guo, J., Zhao, X., Huang, H., Zhang, J., Chen, X., Wang, Q., et al. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.03.003 · Cited by 65
Dhir, A., & Kulkarni, S. K. (2007) · Pharmacology · doi:10.1159/000104877 · Cited by 62
Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor
Xue, R., Jin, Z., Chen, H., Li, Y., He, X., Zhang, Y., Meng, Y., Xu, J., Zheng, J., Zhong, B., et al. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.001 · Cited by 59
Sonne, C., Carlsson, J., Bech, P., Elklit, A., & Mortensen, E. L. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1081-5 · Cited by 56
“As stated above, venlafaxine has shown promising results in non-refugee PTSD populations, but has only been compared to SSRIs in one small refugee study of limited quality.”
BackgroundInfluentialGonçalves, A. E., Bürger, C., Amoah, S. K. S., Tolardo, R., Biavatti, M. W., & de Souza, M. M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.009 · Cited by 55
“In previous studies, this treatment regimen of PCPA produced around 60–90% depletion of brain serotonin concentration in rats (Redrobe et al., 1998; Wang et al., 2008).”
BackgroundMethodPlurality of anxiety and depression alteration mechanism by oleanolic acid
Fajemiroye, J. O., Galdino, P. M., Florentino, I. F., da Rocha, F. F., Ghedini, P. C., Polepally, P. R., Zjawiony, J. K., & Costa, É. A. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114536789 · Cited by 51
“The regimen of PCPA in this study is known to deplete about 60% of endogenous storage of serotonin content without altering the noradrenaline or dopamine levels (Kwon et al., 2010; Redrobe et al., 1998a, 1998b).”
BackgroundNeuropharmacology of venlafaxine
Roseboom, P. H., & Kalin, N. H. (2000) · Depression and Anxiety · doi:10.1002/1520-6394(2000)12:1+<20::aid-da3>3.0.co;2-m · Cited by 56
Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo
Gur, E., Dremencov, E., Lerer, B., & Newman, M. E. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00164-8 · Cited by 52
Guzzetti, S., Calcagno, E., Canetta, A., Sacchetti, G., Fracasso, C., Caccia, S., Cervo, L., & Invernizzi, R. W. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.031 · Cited by 49
“…C57BL/ 6N mice is consistent with previous studies reporting no effects of pCPA or the selective destruction of serotonergic neurons with the neurotoxin 5,7-dihydroxytryptamine in mice and rats (Borsini, 1995; Cervo and Samanin, 1991; Gavioli et al., 2004; Page et al., 1999; Redrobe et al., 1998).”
MethodTail-suspension induced hyperthermia: a new measure of stress reactivity
Liu, X., Peprah, D., & Gershenfeld, H. K. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00004-9 · Cited by 47
The Antidepressant-like Effect of Physical Activity on a Voluntary Running Wheel
Cunha, M. P., Oliveira‐Giacomelli, Á., Pazini, F. L., Machado, D. G., Bettio, L. E. B., Budni, J., Aguiar, A. S., Martins, D. F., Santos, A. R. S., & Rodrigues, A. L. S. (2013) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31827b23e6 · Cited by 54
“PCPA, a tryptophan hydroxylase inhibitor, at same dose used in the present study produced partial but highly significant reductions on brain 5-HT levels (È60%), without affecting NA and DA levels in mice (29).”
BackgroundMethodBerrocoso, E., & Micó, J. A. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008766 · Cited by 52
“Thus, it could be contended that venlafaxine exhibits antidepressant-like effects starting with doses that have been related to 5-HT reuptake whereas the contribution of both monoamines are necessary for the antinociceptive effect (Marchand et al., 2003 ; Redrobe et al., 1998).”
BackgroundDhir, A., & Kulkarni, S. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.02.011 · Cited by 44
Kumarnsit, E., Vongvatcharanon, U., Keawpradub, N., & Intasaro, P. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.01.061 · Cited by 43
Yan, T., Xu, M., Wu, B., Liao, Z., Liu, Z., Zhao, X. D., Kai-shun, B., & Jia, Y. (2016) · Food & Function · doi:10.1039/c6fo00328a · Cited by 45
Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats
Santos-Junior, J. G., Monte, F. H. D., Russi, M. A., Agustine, P. E., & Lanziotti, V. M. N. B. (2002) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2002000400010 · Cited by 41
Kumar, A., Garg, R., Gaur, V., & Kumar, P. (2009) · Brain Research · doi:10.1016/j.brainres.2009.11.050 · Cited by 44
“Venlafaxine is a novel antidepressant, selectively inhibits reuptake of both serotonin as well as norepinephrine (Redrobe et al., 1998).”
Phantom limb pain: a review of pharmacological management
Hall, N., & Eldabe, S. S. (2017) · British Journal of Pain · doi:10.1177/2049463717747307 · Cited by 48
Khanassov, V., Hu, J., Reeves, D., & van Marwijk, H. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4974 · Cited by 44
Rajkumar, R., Pandey, D. K., Mahesh, R., & Radha, R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.041 · Cited by 41
Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine
Coutens, B., Yrondi, A., Rampon, C., & Guiard, B. P. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06203-8 · Cited by 56
Carlini, V. P., Poretti, M. B., Rask-Andersen, M., Chavan, R. A., Ponzio, M. F., Sawant, R. S., de Barioglio, S. R., Schiöth, H. B., & de Cuneo, M. F. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.03.004 · Cited by 39
Pesarico, A. P., Sampaio, T. B., Stangherlin, E. C., Mantovani, A. C., Zeni, G. R., & Nogueira, C. W. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.001 · Cited by 41
Antidepressant-like effects of glucagon-like peptide-2 in mice occur via monoamine pathways
Iwai, T., Hayashi, Y., Narita, S., Kasuya, Y., Jin, K., Tsugane, M., & Oka, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.020 · Cited by 41
Is There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38
“Venlafaxine is a phenylethylamine derivative inhibiting the reuptake of serotonin/5-HT; norepinephrine/NE; and to a lesser extent dopamine/DA (Bolden-Watson and Richelson, 1993; Redrobe et al., 1998).”
BackgroundBerrocoso, E., Rojas-Corrales, M. O., & Micó, J. A. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.03.041 · Cited by 41
Rojas, P. S., Fritsch, R., Rojas, R., Jara, P., & Fiedler, J. L. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.04.032 · Cited by 41
“Venlafaxine is a dual-acting antidepressant, showing effects similar to SSRIs at low doses and blocking both the serotonergic and the noradrenergic transporter at higher doses, as inferred from in vitro studies (Redrobe et al., 1998).”
BackgroundInvolvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine.
Dhir, A., & Kulkarni, S. K. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.04.055 · Cited by 39
Tian, Y., Du, J., Spagna, A., Mackie, M.-A., Gu, X., Dong, Y., Fan, J., & Wang, K. (2016) · Scientific Reports · doi:10.1038/srep28028 · Cited by 36
The four-plates test: Anxiolytic or analgesic paradigm?
Ripoll, N., Hascoët, M., & Bourin, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.036 · Cited by 37
Self-citationDekeyne, A., Gobert, A., Auclair, A. L., Girardon, S., & Millan, M. J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1070-x · Cited by 36
“Venlafaxine displays robust effects in virtually all preclinical models predictive of antidepressant properties, is active in experimental protocols of impulsive behaviour (Schweizer et al. 1997; Redrobe et al. 1998; Millan et al. 2001a) and generalises to discriminative stimuli elicited by the NARI reboxetine and the…”
BackgroundTriple reuptake inhibitors: a patent review (2006 – 2012)
Shao, L., Li, W., Xie, Q., & Yin, H. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.859676 · Cited by 36
“As second generation of MATs inhibitors, dual uptake inhibitors such as venlafaxine 4, milnacipran 5 and duloxetine 6 (Figure 2) offered better antidepressant efficacy [8].”
BackgroundUmukoro, S., Adebesin, A., Agu, G., Omorogbe, O., & Asehinde, S. (2017) · Advances in Medical Sciences · doi:10.1016/j.advms.2017.07.005 · Cited by 35
Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine
Busanello, A., Peroza, L. R., Wagner, C., Sudati, J. H., Pereira, R. P., Prestes, A. D. S., da Rocha, J. B. T., Fachinetto, R., & Barbosa, N. V. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.007 · Cited by 31
Teixeira, C. P. L., de Melo, C. T. V., de Araújo, F. L. O., de Carvalho, A. M. R., Silva, M. I. G., Barbosa‐Filho, J. M., Macêdo, D. S., Viana, G. S. D. B., & de Sousa, F. C. F. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00973.x · Cited by 41
Narasingam, M., Vijeepallam, K., Mohamed, Z., & Pandy, V. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.148 · Cited by 38
“It has been reported that the daily administration of PCPA for four consecutive days showed a significant reduction of the endogenous storage of serotonin by about 60% in mice without significantly altering noradrenaline or dopamine levels [36].”
Singh, M. P., Singh, K. P., Shukla, S., & Dikshit, M. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.10.007 · Cited by 31
“E-mail address: kps29@rediffmail.com (K.P. Singh). mode of action (Benkert et al., 2006; Preskorn, 1997; Redrobe et al., 1998).”
Gill, J. S., Jamwal, S., Kumar, P., & Deshmukh, R. R. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.11.008 · Cited by 31
Piacentini, M. F., Clinckers, R., MEEUSEN, R. R., Sarre, S., Ebinger, G., & Michotte, Y. M. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00658-1 · Cited by 32
Berrocoso, E., & Micó, J. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120915 · Cited by 34
“In addition, parachlorophenylalanine, an inhibitor of 5-HT synthesis, blocked both effects (Redrobe et al., 1998; Marchand et al., 2003), suggesting that the noradrenergic and serotonergic systems participate in the antidepressant and analgesic effect of venlafaxine.”
BackgroundSugimoto, Y., Nishimura, K., Itoh, A., Tanahashi, T., Nakajima, H., Oshiro, H., Sun, S., Toda, T., & Yamada, J. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12473 · Cited by 32
“Previous reports suggested that the treatment with PCPA in this study could decrease brain 5-HT levels (over 60%), whereas noradrenaline and dopamine levels are not altered.([18,19])”
Melichar, J., Haida, A., Rhodes, C., Reynolds, A. H., Nutt, D. J., & Malizia, A. L. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500102 · Cited by 30
O’Leary, O. F., Zandy, S. L., Dinan, T. G., & Cryan, J. F. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.072 · Cited by 30
Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice
Ludka, F. K., Constantino, L. C., Kuminek, G., Binder, L. B., Zomkowski, A. D. E., Cunha, M. P., Dal-Cim, T. A., Rodrigues, A. L. S., & Tasca, C. I. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.04.005 · Cited by 28
Oleanolic acid acrylate elicits antidepressant-like effect mediated by 5-HT1A receptor
Fajemiroye, J. O., Polepally, P. R., Chaurasiya, N. D., Tekwani, B. L., Zjawiony, J. K., & Costa, É. A. (2015) · Scientific Reports · doi:10.1038/srep11582 · Cited by 29
Mansouri, M. T., Naghizadeh, B., Ghorbanzadeh, B., Amirgholami, N., Houshmand, G., & Alboghobeish, S. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00491-4 · Cited by 30
Day, C. V., Rush, A. J., Harris, A. W. F., Boyce, P. M., Rekshan, W. R., Etkin, A., DeBattista, C., Schatzberg, A. F., Arnow, B. A., & Williams, L. M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.046 · Cited by 24
“While the average dose of venlafaxine-XR dosage was lower than the suggested noradrenergic threshold of 150 mg (Clerc et al., 1994; Redrobe et al., 1998), remission and response did not significantly differ when the sample was grouped into o150 mg and Z150 mg. Similarly, melancholic MDD was also…”
BackgroundAyres, A. S. F. S. J., Santos, W. B., Junqueira-Ayres, D. D., Costa, G. M., Ramos, F. A., Castellanos, L., Alves, J. S. F., Asth, L., de Medeiros, Í. U., Zucolotto, S. M., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.010 · Cited by 25
Gautam, B., Jindal, A., Dhar, A. K., & Mahesh, R. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.05.006 · Cited by 27
Effect of repetitive transcranial magnetic stimulation on forced swimming test
Tsutsumi, T., Fujiki, M., Akiyoshi, J., Horinouchi, Y., Isogawa, K., Hori, S., & Nagayama, H. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00227-5 · Cited by 25
Kitaichi, Y., Inoue, T., Nakagawa, S., Izumi, T., & Koyama, T. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.04.038 · Cited by 23
da Silva, D. M., Sanz, G., Vaz, B. G., de Carvalho, F. S., Lião, L. M., de Oliveira, D. R., Moreira, L. K. D. S., Cardoso, C. S., de Brito, A. F., da Silva, D. P. B., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.077 · Cited by 26
Rahman, Z. U., Ring, R. H., Young, K. A., Platt, B. J., Lin, Q., Schechter, L. E., Rosenzweig-Lipson, S. J., & Beyer, C. E. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.062 · Cited by 28
The Forced Swimming Test in Mice: A Suitable Model to Study Antidepressants
Hascoët, M., & Bourin, M. (2009) · Neuromethods · doi:10.1007/978-1-60761-303-9_6 · Cited by 26
Self-citationFrancesconi, G., Orsolini, L., Papanti, D., Corkery, J. M., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2476 · Cited by 22
“At high/very high dosages, venlafaxine presents as well with significant 5-HTergic activity (Redrobe et al., 1998; Harvey et al., 2000), hence mimicking the MDMA/ecstasy effects (Schifano, 2004).”
BackgroundPoretti, M. B., Sawant, R. S., Rask‐Andersen, M., de Cúneo, M. F., Schiöth, H. B., Pérez, M. F., & Carlini, V. P. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4187-4 · Cited by 24
Einat, H., Belmaker, R. H., Zangen, A., Overstreet, D. H., & Yadid, G. (2002) · Depression and Anxiety · doi:10.1002/da.10025 · Cited by 22
“The present study cannot by itself lead to any direct mechanistic conclusions and further studies are needed using techniques such as microdialysis [e.g., Zangen et al., 1997] or pharmacological dissection of the behavior [e.g., Redrobe et al., 1998].”
MethodNo Effect of a Selective Serotonergic/Noradrenergic Reuptake Inhibitor on Endurance Performance
Piacentini, M. F., MEEUSEN, R. R., Buyse, L., Schutter, G. D., & Meirleir, K. D. (2002) · European Journal of Sport Science · doi:10.1080/17461391.2002.10142578 · Cited by 22
The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor
Xue, R., Zhang, Y., Jin, Z., Yuan, L., He, X., Zhao, N., Chen, H., Zhang, L., Fan, S.-Y., Zhong, B., et al. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.076 · Cited by 22
Neoechinulin A induced memory improvements and antidepressant-like effects in mice
Sasaki‐Hamada, S., Hoshi, M., Niwa, Y., Ueda, Y., Kokaji, A., Kamisuki, S., Kuramochi, K., Sugawara, F., & Oka, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.08.002 · Cited by 21
“…for 4 consecutive days, has been reported to inhibit tryptophan hydroxylase, inhibit 5-HT synthesis, and deplete endogenous stores of 5-HT in the central nervous system by 60–90% in mice, with no effect on noradrenaline or dopamine levels (Koe and Weissman, 1966; Redrobe et al., 1998a, 1998b).”
BackgroundHood, S. D., Hince, D., Davies, S., Argyropoulos, S. V., Robinson, H., Potokar, J. P., & Nutt, D. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1722-1 · Cited by 27
“We are aware that at low-dose venlafaxine has the properties of a serotonergic antidepressant (Melichar et al. 2001; Redrobe et al. 1998 ) and that, ideally, patients would have been remitted with a single type of SSRI; however, as the study cohort was drawn from a naturalistic outpatient clinic sample, a variety of s…”
Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models
Réus, G. Z., de Moura, A. B., Borba, L. A., Abelaira, H. M., & Quevedo, J. (2019) · Complex Psychiatry · doi:10.1159/000500324 · Cited by 22
Metadata
- Authors
- Redrobe, J. P., Bourin, M., Colombel, M. C., & Baker, G. B.
- Affiliations
- Nantes Université (FR)
- Venue
- Psychopharmacology
- Published
- 1998-07-01
- Volume
- 138
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2037662525
- Cited by
- 163
- References
- 24
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 8 · 2014: 7 · 2013: 9 · 2012: 11
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- venlafaxine, antidepressant effects, serotonin reuptake inhibition, norepinephrine reuptake inhibition, dose-dependent effects, forced swim test, immobility, locomotor activity, NAN-190, p-chlorophenylalanine, DSP-4, pindolol, RU 24969, 8-OH-DPAT, clonidine, lithium, quinine
- MeSH terms
- Venlafaxine Hydrochloride, Animals, Cyclohexanols, Male, Motor Activity, Pindolol, Piperazines, Selective Serotonin Reuptake Inhibitors, 8-Hydroxy-2-(di-n-propylamino)tetralin, Antidepressive Agents, Second-Generation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.